-
241
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in μM range.
Pubblicazione 2025Soggetti: -
242
-
243
-
244
The alternative model 3.0.1 with reduced catalytic activity and <i>K</i><sub><i>M</i></sub> values in μM range.
Pubblicazione 2025Soggetti: -
245
-
246
-
247
The null catalytic main model 3.1 with <i>K</i><sub><i>M</i></sub> values in μM range.
Pubblicazione 2025Soggetti: -
248
-
249
-
250
The alternative model 3.0.2 with reduced catalytic activity and <i>K</i><sub><i>M</i></sub> values in 0.1 μM range.
Pubblicazione 2025Soggetti: -
251
-
252
-
253
The null catalytic main model 3.2 and <i>K</i><sub><i>M</i></sub> values in 0.1 μM range.
Pubblicazione 2025Soggetti: -
254
-
255
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in 0.1 μM range.
Pubblicazione 2025Soggetti: -
256
Trialblazers: “Build-a-Trial” workshops for people with psoriatic arthritis
Pubblicazione 2024“...This was to be followed in June 2024 by an application to the Medical Research Council (MRC) funding stream for a grant in understanding public involvement in non-clinical research.</p><p dir="ltr">In collaboration with the NDORMS’ public-involvement group, Open Arms, and led by clinician researcher Laura Coates, the team developed and ran Build-a-Trial workshops with patients to design this much needed trial from scratch. ...”
-
257
-
258
-
259
-
260
Results for each experimental case (as numbered in Fig 3 with their respective color).
Pubblicazione 2022Soggetti: